Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 312Pharmacogenetics and Drug MetabolismLung Cancer Treatments and MutationsSmoking Behavior and Cessation

The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.

Effects of Smoking on the Pharmacokinetics of Erlotinib

Hamilton, Marta, Wolf, Julie L., Rusk, Jason, Beard, Shannon E., Clark, Gary M., Witt, Karsten, Cagnoni, Pablo J.·2006·Clinical Cancer Research

Abstract

Purpose: To compare the pharmacokinetic variables of erlotinib in current smokers with nonsmokers after receiving a single oral 150 or 300 mg dose of erlotinib. Experimental Design: This was a single-center, open-label pharmacokinetic study in healthy male subjects. Subjects were enrolled into two treatment cohorts based on smoking status (current smokers and nonsmokers). The pharmacokinetic profile for erlotinib and its metabolite, OSI-420, was determined for each subject following each treatment. Results: Current smokers achieved significantly less erlotinib exposure following a single 150 or 300 mg dose than nonsmokers. Following the 150 mg dose, the geometric mean erlotinib AUC0-∞ in smokers was 2.8-fold lower than in nonsmokers and similar to that of nonsmokers at the 300 mg dose. Cmax in smokers was two-thirds of that in nonsmokers, and C24h in smokers was 8.3-fold lower than in nonsmokers. The median C24h of smokers at the 300 mg dose was slightly less than the C24h of smokers at the 150 mg dose. The median Cmax was greater in smokers at the 300 mg dose than in nonsmokers at the 150 mg dose. Conclusion: This study confirms that the pharmacokinetics of erlotinib is different in current smokers and nonsmokers. The observation that AUC0-∞ and C24h were significantly decreased in smokers compared with nonsmokers, and a smaller decrease in Cmax was observed, is consistent with increased metabolic clearance of erlotinib in current smokers.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-05-2235

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 2

  1. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. N Engl J Med 2005;353:123–32. · doi:10.1200/jco.2004.22.90140.7022 · Paper page
  2. Hamilton M, Wolf JL, Zborowski D, et al. Tarceva™ (erlotinib) exposure/effects (EE) analysis from a phase III study in advanced NSCLC: effect of smoking on the PK of erlotinib [abstract 6165]. Proc Am Assoc Cancer Res 2005;46:1451.

Cited by

See all 312

Metadata

Authors
Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J.
Affiliations
Authors' Affiliation: OSI Pharmaceuticals, Inc., Boulder, Colorado
Venue
Clinical Cancer Research
Published
2006-04-01
Volume
12
Issue
7
Pages
2166-2171
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2159023488
Cited by
312
References
27
Citations by year
2026: 4 · 2025: 11 · 2024: 5 · 2023: 4 · 2022: 9 · 2021: 10 · 2020: 15 · 2019: 16 · 2018: 17 · 2017: 12 · 2016: 16 · 2015: 24 · 2014: 22 · 2013: 27 · 2012: 18
FWCI
16.11
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Keywords
erlotinib, smoking, pharmacokinetics, drug metabolism, metabolic clearance, smokers versus non-smokers, AUC, Cmax, dose comparison
MeSH terms
Erlotinib Hydrochloride, Adult, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Male, Middle Aged, Quinazolines, Reference Values, Safety, Smoking, Time Factors, Cohort Studies, Molecular Structure, Cross-Over Studies, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Smoking on the Pharmacokinetics of Erlotinib. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-2235
The paper
Hamilton, M., Wolf, J. L., Rusk, J., Beard, S. E., Clark, G. M., Witt, K., & Cagnoni, P. J. (2006). Effects of Smoking on the Pharmacokinetics of Erlotinib. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-2235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.